<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00051584</url>
  </required_header>
  <id_info>
    <org_study_id>SG015-0003</org_study_id>
    <nct_id>NCT00051584</nct_id>
    <nct_alias>NCT00056017</nct_alias>
  </id_info>
  <brief_title>Safety/Efficacy Study of SGN-15 (Antibody-Drug Conjugate) Combined With Gemcitabine in Patients With Ovarian Cancer</brief_title>
  <official_title>A Phase II Study of SGN-15 (cBR96 - Doxorubicin Immunoconjugate) Combined With Gemzar® Versus Single-Agent Gemzar® in Patients With Advanced Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seagen Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seagen Inc.</source>
  <brief_summary>
    <textblock>
      This is an open-label, randomized phase II trial comparing treatment with a monoclonal&#xD;
      antibody (mAb) drug immunoconjugate, SGN-15, administered weekly in combination with weekly&#xD;
      Gemzar® (Gemcitabine) to treatment with Gemzar® alone. The primary objectives of this study&#xD;
      are to determine the toxicity and safety profile of the combination of SGN-15 and Gemzar®, to&#xD;
      estimate the clinical response rate and to estimate the duration of response of this&#xD;
      combination therapy administered to patients with advanced ovarian cancer, compared to&#xD;
      treatment with Gemzar® alone.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <completion_date type="Actual">May 2003</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>60</enrollment>
  <condition>Ovarian Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGN-15 (cBR96-Doxorubicin Immunoconjugate)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemzar (Gemcitabine)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Brief Overview of Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have pathologically confirmed ovarian cancer, which is advanced or&#xD;
             recurrent carcinoma, who have failed at least two, but no more than three prior&#xD;
             therapies for metastatic disease&#xD;
&#xD;
          -  Patients must have &gt; 20% Lewis-y antigen expression documented by immunohistochemistry&#xD;
&#xD;
          -  LVEF &gt; 50% by echo or MUGA&#xD;
&#xD;
          -  Must be platinum resistant as defined by:&#xD;
&#xD;
               -  Progression while on initial platinum therapy or&#xD;
&#xD;
               -  Progression while on retreatment with initial platinum regimen or&#xD;
&#xD;
               -  Relapse &lt; 6 months after initial therapy&#xD;
&#xD;
        Brief Overview of Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have had prior therapy with Gemzar®&#xD;
&#xD;
          -  Cumulative anthracycline exposure &gt; 300 mg/m2&#xD;
&#xD;
          -  More than three prior chemotherapy regimens for ovarian cancer (Retreatment with&#xD;
             Taxane/Platinum after initial combination is considered only one regimen)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Sandler, MD</last_name>
    <role>Study Director</role>
    <affiliation>Seagen Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sharp Healthcare</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Hematology Oncology Medical Group</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mountain States Tumor Institute</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arlington Fairfax Hematology Oncology</name>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <zip>22205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <study_first_submitted>January 13, 2003</study_first_submitted>
  <study_first_submitted_qc>January 14, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2003</study_first_posted>
  <last_update_submitted>October 21, 2011</last_update_submitted>
  <last_update_submitted_qc>October 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2011</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Immunoconjugates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

